NATAP/EASL:乙肝肾功能异常

StephenW

> Subject: NATAP/EASL: HBV & Renal Abnormalities
>
> HARPE Study: Prevalence of Renal Abnormalities in Chronic Hepatitis B Virus Infection - see attached full poster report
>
>  

>
>  
>
> Reported by Jules Levin
>
> EASL 2013 April 24-28 Amsterdam
> S Amet1, J-P Bronowicki2, D Thabut3, F Zoulim4, M Bourliere5, P Mathurin6, V de Ledinghen7, Y Benhamou3, D Larrey8, E Bruce1, N Janus1, V Launay-Vacher1, G Deray9, S Pol10.
>
> 1.Service ICAR - Nephrology Department, Pitie Salpetriere Hospital, Paris; 2.Hepatology Department, Brabois Hospital, Vandoeuvre-les-Nancy; 3.Hepatology Department, Pitie Salpetriere Hospital, Paris; 4. HepatologyDepartment, Croix Rousse Hospital, Lyon; 5. Hepatology Department, Saint Joseph Hospital, Marseille; 6. Hepatology Department, Claude Huriez Hospital, Lille; 7. Hepatology Department, Haut Leveque Hospital, Pessac; 8. Hepatology Department, Saint Eloi Hospital, Montpelllier; 9. Nephrology Department, Pitie Salpetriere Hospital, Paris; 10. Paris 5 University, Inserm U-1016, Hepatology Department, Cochin Hospital, Paris. All from France.
>
>
> Conclusion
>
> Renal abnormalities are present in 1/3 and CKD (chronic Kidney Disease)in 1/4 of HBsAg (+) patients,
> regardless of the immune stage and before any oral anti-HBV treatment (AT),
> evidencing the need for:
> 1. a renal evaluation in all;
> 2. a regular renal monitoring before and during anti-HBV treatments to diagnose and
> manage renal impairment and adjust dose of AT to the renal function.

>肾功能异常是本以1/3，

CKD(慢性肾脏病)

1/4的HBsAg（+）患者中，
无论免疫阶段之前任何口服抗HBV治疗（AT），
>证明的必要性：
> 1。肾在所有的评价;
> 2。定期肾抗乙肝病毒治疗之前和期间的诊断和监控
>管理肾功能不全和肾功能调整剂量AT。